Evidence map›Paper›PMID 34119472›Full record

ArticleThe American journal of pathology2021

CUL4

Yannan Wang, Fan Yan, Abu Nasar, Zhe-Sheng Chen, Nasser Khaled Altorki, Brendon Stiles, Navneet Narula, Pengbo Zhou

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yannan WangDepartment of Pathology and Laboratory Medicine, The Joan and Stanford I. Weill Medical College of Cornell University, New York, New York.
Fan YanDepartment of Pathology and Laboratory Medicine, The Joan and Stanford I. Weill Medical College of Cornell University, New York, New York.
Abu NasarDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St John's University, Queens, New York.
Nasser Khaled AltorkiDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York.
Brendon StilesDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York.
Navneet NarulaDepartment of Pathology and Laboratory Medicine, The Joan and Stanford I. Weill Medical College of Cornell University, New York, New York.
Pengbo ZhouDepartment of Pathology and Laboratory Medicine, The Joan and Stanford I. Weill Medical College of Cornell University, New York, New York. Electronic address: pez2001@med.cornell.edu.
Cornell University · USNewYork–Presbyterian Hospital · USSt. John's University · US

Funding

Harnessing the CRL4 ubiquitin ligase for antagonizing colorectal carcinogenesisR01CA213992 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ZHOU, PENGBO · 2017 to 2021
$2.7M
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate TumorigenesisR01CA221152 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ZHOU, PENGBO · 2018 to 2022
$2.4M
NCI NIH HHS R01 CA213992NCI NIH HHS R01 CA221152
6 · The paper itself

Abstract

Cullin (CUL) 4A and 4B ubiquitin ligases are often highly accumulated in human malignant neoplasms and are believed to possess oncogenic properties. However, the underlying mechanisms by which CUL4A and CUL4B promote pulmonary tumorigenesis remain largely elusive. This study reports that CUL4A and CUL4B are highly expressed in patients with non-small cell lung cancer (NSCLC), and their high expression is associated with disease progression, chemotherapy resistance, and poor survival in adenocarcinomas. Depletion of CUL4A (CUL4A

Indexed as

Adenocarcinoma of LungAnimalsBiomarkersCell ProliferationCell SurvivalCullin ProteinsCyclin-Dependent Kinase Inhibitor p21Disease ProgressionDrug Resistance, NeoplasmFemaleHeterograftsHumansLung NeoplasmsMiceMice, NudePrognosisBiomarkersCDKN1A protein, humanCUL4A protein, humanCUL4B protein, humanCullin ProteinsCyclin-Dependent Kinase Inhibitor p21Ubiquitin

Identifiers

PMID34119472
PMCPMC8420861
OpenAlexW3171344983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.